0+
Cell & Gene Therapy Leaders From Asia
0+
Companies
0+
Speakers Sharing Their Expertise
0+
In-Person Networking
0+
Case Studies
reverse process
The Concept

Into its 2nd edition, Stem Cells and Regenerative Medicine Asia 2022 has firmly established itself as Asia's THE regenerative medicines gathering for new partnerships, ideas and knowledge. We are proud to continue the meeting platform where Asia's growing regenerative therapy industry is at the forefront, receiving more and more global attention on its fast advancement in new therapies, R&D and biomanufacturing.

Download Brochure
2022 Speakers
Past Program

The global stem cell therapy market is expected to grow at a CAGR of 16.5 percent to USD 401 million by 2026, up from USD 187 million in 2021. Due to the growing production of stem cell-based therapies, government initiatives for developing regenerative medicines, the establishment of many stem cell banks, and increasing clinical trials for regenerative medicines in the region, Asia Pacific is expected to grow at the fastest CAGR of 9.0 percent during the forecast year. For example, MEDIPOST, Korea announced the results of NEUROSTEM's phase 1/2a study in July 2020. It's an experimental stem cell therapy for the treatment of Alzheimer's disease.

To combat the pandemic, researchers have been developing new therapies and treatments. Stem cells have been shown to be an effective treatment for pulmonary disorders, like COVID-19, in recent years.

In addition, the increasing number of product development initiatives in this field, combined with the presence of several marketed products, has resulted in a significant increase in overall cell therapy manufacturing demand. As a result, cell therapy developers have turned to contract manufacturing organizations (CMOs) to meet their growth and production needs.

These opportunities include contract research and manufacturing outsourcing and rising patient population with neurological and other chronic conditions in the region. China, Japan, Singapore, and South Korea are the frontrunners and are set to dominate the APAC stem cell market in the coming year.

Adult stem cell leads the market due to low contamination during sub-culture and expansion, relatively small labor production and compatibility with the human body. Just the Induced pluripotent stem cells (IPSc’s) was expected to report revenue of over USD 4.5 billion by 2020, on account of the similar nature of its origin. With the continued growth of medical tourism hubs like India, Singapore, and Thailand, Asia is expected to maintain its place as the epicenter of stem cell research and therapy. These opportunities include contract research outsourcing and rising patient population with neurological and other chronic conditions in the region. Japan, Singapore, and South Korea are the frontrunners and are set to dominate the APAC stem cell market in the coming years.

Case Studies on Stem Cells & Regenerative Medicines from Taiwan

Gain insights on the latest case studies of stem cell and regenerative medicine and recognize the potential of the cell and gene therapies.

Advances in CAR-T Cell Therapy Development

Explore the latest CAR-T cell therapy advancements with impressive and effective solutions for antitumor treatments, especially against hematological malignancies from Taiwan's key leaders in the CAR-T cell therapy industry.

Cell & Gene Therapy Manufacturing Best Practices

Immerse in the best practices of cell & gene therapy products from the innovative showcase of the Taiwan market while considering the key factors and strategy that can lead to successful scale up and manufacturing of the products.

Cell & Gene Therapy Commercialization Strategies

Listen to the key industry leaders of cell & gene therapy about their success stories of making the commercialization of the products a successful ones while replicating the strategies of effective manufacturing and commercialization in the market.

Innovative Treatments in Cell & Gene Therapy from Taiwan

While Asia region countries like China, Korea and Japan are advancing the cell & gene therapy sector, Taiwan has also come up with innovative treatment alternatives that help to save people's lives. Dive deep into the latest innovation of cell & gene therapy from the Taiwan stories and get amazed!

Download Brochure

LIMITED SPECIAL- END USER

SGD 2595 (Save SGD 600)
  • 2- Day Conference Access
  • Expires 24th June
  • Full Price SGD 3195

LIMITED SPECIAL- VENDOR/BD

SGD 4395 (Save SGD 500)
  • 2- Day Conference Access
  • Expires 24th June
  • Full Price SGD 4895
1
Thought Leadership

Present your expertise to the key cell and gene therapy stakeholders from Asia through a variety of available speaking packages.

2
Exhibit

Join the exhibition, and build an impressive presence among your potential clients.

3
Branding

Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.

4
Networking

Engage with and build lasting connections that matter the most to your business.

5
Lead Generation

Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.

bag